Ionis Pharmaceuticals reported a quarterly loss of $0.30 per share, beating the Zacks Consensus Estimate for a $0.85 loss by $0.55 per share. The result also improved from a loss of $0.75 per share in the same quarter a year ago, indicating better-than-expected earnings performance and year-over-year improvement. The release is positive for the stock, though the article provides no revenue or guidance details.
Ionis Pharmaceuticals reported a quarterly loss of $0.30 per share, beating the Zacks Consensus Estimate for a $0.85 loss by $0.55 per share. The result also improved from a loss of $0.75 per share in the same quarter a year ago, indicating better-than-expected earnings performance and year-over-year improvement. The release is positive for the stock, though the article provides no revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
